303.1: Prolonged CD38 targeting with felzartamab achieves sustained suppression of antibody-mediated rejection in kidney transplant recipients: A biomarker-guided open-label phase 2 extension.
Year: 2026
Type: article
Source: Transplantation
Authors: Katharina Mayer, Matthias Diebold, Eva V Schrezenmeier, Philip F Halloran, Susanne Haindl, Martina Schatzl, Aylin Akifova, Daniela M Allmer, Sabine Schranz, Nicolas Kozakowski, Johannes Kläger, Kerstin Amann, Julia Beck, Ekkehard Schütz, Maarten Naesens, Alexandre Loupy, Irene Görzer, Hannes Vietzen, Gordon Ingle, Donna L Flesher, Uptal D Patel, Fabian Halleck, Irene Graf, Bernd Jilma, Klemens Budde, Georg A Böhmig
Institutions: Medical University of Vienna, University of Basel, University Hospital of Basel, Charité – Universitätsmedizin Berlin, University of Alberta, Friedrich-Alexander-Universität Erlangen-Nürnberg, Niedersächsische Staats- und Universitätsbibliothek Göttingen, KU Leuven, Inserm, Biogen (United States)
Language: English
Subfield: Transplantation
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7204750149
FWCI:
Cites:
Cited by:
Related to: